Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of Tuberous Sclerosis Complex

Keyphrases

• TSC1 100%
• Tuberous Sclerosis Complex 100%
• Mouse Model 100%
• Epilepsy Phenotype 100%
• Gene Inactivation 100%
• Mammalian Target of Rapamycin (mTOR) 25%
• Epilepsy 25%
• Neurological Phenotype 25%
• TSC1 mutation 25%
• TSC2 mutation 25%
• Autosomal Dominant 12%
• Early Onset 12%
• Astrocytes 12%
• Glial Fibrillary Acidic Protein 12%
• Rapamycin 12%
• Autism 12%
• Multisystem Disease 12%
• Neurological Manifestations 12%
• Clinical Phenotype 12%
• Glutamate Transporter 1 (GLT-1) 12%
• Cognitive Deficits 12%
• Seizure Frequency 12%
• Premature Death 12%
• MTOR Inhibitor 12%
• Neurological Symptoms 12%
• Pyramidal Neurons 12%
• Transporter Expression 12%
• Conditional Inactivation 12%
• Glial Proliferation 12%
• Histological Abnormalities 12%
• Hamartin 12%
• Tuberin 12%

Neuroscience

• Mammalian Target of Rapamycin 100%
• Tuberous Sclerosis 100%
• TSC1 100%
• Gene Inactivation 100%
• Cognitive Disorders 33%
• Glial Fibrillary Acidic Protein 33%
• Astrocyte 33%
• Pervasive Developmental Disorder 33%
• Pyramidal Cell 33%
• Glutamate Transporter 33%
• Hamartin 33%
• Tuberin 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Mouse 100%
• Mouse Model 100%
• Tuberous Sclerosis 100%
• Mammalian Target of Rapamycin 25%
• Disease 12%
• Prematurity 12%
• Neurologic Disease 12%
• Rapamycin 12%
• Cognitive Defect 12%
• Mammalian Target of Rapamycin Inhibitor 12%
• Glial Fibrillary Acidic Protein 12%
• Hamartin 12%
• Glutamate Transporter 12%
• Tuberin 12%